Speri Enrico, Qian Yuanyuan, Janardhanan Jeshina, Masitas Cesar, Lastochkin Elena, De Benedetti Stefania, Wang Man, Schroeder Valerie A, Wolter William R, Oliver Allen G, Fisher Jed F, Mobashery Shahriar, Chang Mayland
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Freimann Life Sciences Center, University of Notre Dame, Notre Dame, Indiana 46556, United States.
ACS Med Chem Lett. 2021 May 7;12(6):991-995. doi: 10.1021/acsmedchemlett.1c00135. eCollection 2021 Jun 10.
is a leading health threat. This pathogen initiates intestinal infections during gut microbiota dysbiosis caused by oral administration of antibiotics. is difficult to eradicate due to its ability to form spores, which are not susceptible to antibiotics. To address the urgent need for treating recurrent infection, antibiotics that selectively target over common gut microbiota are needed. We herein describe the class of picolinamide antibacterials which show potent and selective activity against . The structure-activity relationship of 108 analogues of isonicotinamide , a compound that is equally active against methicillin-resistant and , was investigated. Introduction of the picolinamide core as exemplified by analogue resulted in exquisite potency and selectivity against . The ability of the picolinamide class to selectively target and to prevent gut dysbiosis holds promise for the treatment of recurrent infection.
是一种主要的健康威胁。这种病原体在口服抗生素导致肠道微生物群失调期间引发肠道感染。由于其形成孢子的能力,这种孢子对抗生素不敏感,所以很难根除。为了满足治疗复发性感染的迫切需求,需要能够选择性地靶向而非普通肠道微生物群的抗生素。我们在此描述了一类对具有强效和选择性活性的吡啶甲酰胺类抗菌剂。研究了异烟酰胺的108种类似物的构效关系,异烟酰胺是一种对耐甲氧西林的和同样有效的化合物。以类似物为例引入吡啶甲酰胺核心,导致对具有出色的效力和选择性。吡啶甲酰胺类选择性靶向并预防肠道失调的能力为治疗复发性感染带来了希望。